The objective of this study is to undertake an initial evaluation of the safety, tolerability, antiviral effect, and pharmacokinetics of celgosivir in combination with peginterferon alfa-2b and ribavirin in patients with chronic HCV infection.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
50
400mg qd + standard of care for 12 weeks
600mg qd + standard of care for 12 weeks
Standard of care for 12 weeks
Liver and Intestinal Research Centre
Vancouver, British Columbia, Canada
RECRUITINGCantest
Vancouver, British Columbia, Canada
COMPLETEDBiovail Contract Research
Toronto, Ontario, Canada
RECRUITINGSafety analysis
Time frame: 12 weeks
HCV viral load
Time frame: 12 weeks
Pharmacokinetics of celgosivir/castanospermine
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.